Platelet transcriptome profiles provide potential therapeutic targets for elderly acute myelocytic leukemia patients.

Journal of Translational Medicine
Jizhang BaoWenwei Zhu


Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with a median age of 68 in clinical diagnosis. About 60% patients are over 60 years old. There are various treatment options for AML patients. But for elderly patients, the complete remission rates are disappointing due to genetic, molecular, and age-related factors. Development of next-generation sequencing technologies makes it possible to seek individual strategies for patients in different ages. This study analyzed transcriptome profiles in platelets of AML patients in different ages for the first time. Platelet RNA sequencing in AML of ten elderly and seven young patients were performed with Illumina TruSeq Stranded mRNA library Prep Kit and Illumina HiSeq4000 sequencing instrument. With the FASTQ sequencing data obtained, statistical analyses between elderly with young AML patients were analyzed by R program. GO and KEGG enrichment analyses were performed via R package clusterProfiler. TOP 10 down-regulated/up-regulated genes in elderly patients compared to young patients were selected with the threshold of |L2FC| > 2 and padj ≤ 0.0001. The down-regulated gene ATF4 was chosen by GSEA analysis and ROC analysis with AUC > 0.95. We found 3059 genes wit...Continue Reading


Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingKonstanze Döhner
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Jun 3, 2008·Nature Methods·Ali MortazaviBarbara Wold
Mar 12, 2010·Nature·Stephen B MontgomeryEmmanouil T Dermitzakis
Nov 15, 2011·Nucleic Acids Research·Minoru KanehisaMao Tanabe
Jul 21, 2012·Current Opinion in Hematology·Jesse W RowleyAndrew S Weyrich
Oct 30, 2012·Bioinformatics·Alexander DobinThomas R Gingeras
Sep 2, 2014·BMC Bioinformatics·Philippe BardouChristophe Klopp
Dec 18, 2014·Blood·Gert Ossenkoppele, Bob Löwenberg
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Sep 19, 2016·Blood Reviews·Jeanette Prada-ArismendySarah Röthlisberger
Aug 12, 2017·Trends in Endocrinology and Metabolism : TEM·Inge M N WortelFrank N van Leeuwen
Sep 22, 2018·Cancers·Beatrice U MuellerThomas Pabst
Jun 12, 2019·Journal of Oncology Practice·Danielle Roberts MMScLeonard T Heffner
Jun 25, 2019·Frontiers in Endocrinology·Miaolong LuXianquan Zhan
Oct 15, 2019·Genomics & Informatics·Sol A JeonSeon-Young Kim
Sep 8, 2020·Seminars in Hematology·Opal L ReddySandhya R Panch

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.